Serina Therapeutics (SER) Common Equity (2017 - 2025)
Historic Common Equity for Serina Therapeutics (SER) over the last 9 years, with Q3 2025 value amounting to $1.8 million.
- Serina Therapeutics' Common Equity rose 11272.78% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 11272.78%. This contributed to the annual value of $641000.0 for FY2024, which is 10198.49% up from last year.
- Latest data reveals that Serina Therapeutics reported Common Equity of $1.8 million as of Q3 2025, which was up 11272.78% from $1.8 million recorded in Q2 2025.
- In the past 5 years, Serina Therapeutics' Common Equity registered a high of $1.8 million during Q2 2025, and its lowest value of -$32.3 million during Q4 2023.
- In the last 5 years, Serina Therapeutics' Common Equity had a median value of -$11.9 million in 2021 and averaged -$11.8 million.
- Its Common Equity has fluctuated over the past 5 years, first tumbled by 72584.57% in 2021, then skyrocketed by 13947.55% in 2025.
- Over the past 5 years, Serina Therapeutics' Common Equity (Quarter) stood at -$11.9 million in 2021, then tumbled by 45.81% to -$17.3 million in 2022, then tumbled by 86.51% to -$32.3 million in 2023, then surged by 101.98% to $641000.0 in 2024, then surged by 174.57% to $1.8 million in 2025.
- Its Common Equity stands at $1.8 million for Q3 2025, versus $1.8 million for Q2 2025 and $1.7 million for Q1 2025.